161 related articles for article (PubMed ID: 30778915)
1. A comparative analysis of the pharmacovigilance systems of Brazil, Spain, the European Union and the United States based on the information provided by their regulatory agency websites.
Leal MM; Sanz MM; Ferrando JRC; Martinez-Martinez F
Daru; 2019 Jun; 27(1):379-387. PubMed ID: 30778915
[TBL] [Abstract][Full Text] [Related]
2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and Perspectives.
Jose J; Rafeek NR
Ther Innov Regul Sci; 2019 Nov; 53(6):781-786. PubMed ID: 30554527
[TBL] [Abstract][Full Text] [Related]
4. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
[TBL] [Abstract][Full Text] [Related]
5. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance in Israel - tools, processes, and actions.
Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
[TBL] [Abstract][Full Text] [Related]
7. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
8. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
9. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
Felix T; Jordan JB; Akers C; Patel B; Drago D
Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
[TBL] [Abstract][Full Text] [Related]
10. Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union.
Inácio P; Cavaco A; Allan E; Airaksinen M
Public Health; 2018 Feb; 155():119-128. PubMed ID: 29346070
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
12. On the clinical evidence leading to tetrazepam withdrawal.
Proy-Vega B; Aguirre C; de Groot P; Solís-García del Pozo J; Jordán J
Expert Opin Drug Saf; 2014 Jun; 13(6):705-12. PubMed ID: 24845943
[TBL] [Abstract][Full Text] [Related]
13. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
14. Selected national pharmacovigilance websites: an analysis of contents.
Barker CI; Talbot JC; Aronson JK
Drug Saf; 2012 Feb; 35(2):141-8. PubMed ID: 22168572
[TBL] [Abstract][Full Text] [Related]
15. Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers.
Klein K; De Bruin ML; Broekmans AW; Stolk P
BioDrugs; 2015 Dec; 29(6):373-9. PubMed ID: 26621793
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
17. [National Pharmacovigilance Systems in Brazil and Portugal: similarities, differences, and challenges].
Pepe VLE; Novaes HMD
Cad Saude Publica; 2020; 36(7):e00043019. PubMed ID: 32696826
[TBL] [Abstract][Full Text] [Related]
18. The Internet and drug safety: what are the implications for pharmacovigilance?
Cobert B; Silvey J
Drug Saf; 1999 Feb; 20(2):95-107. PubMed ID: 10082068
[TBL] [Abstract][Full Text] [Related]
19. Evolution and key elements of the Brazilian pharmacovigilance system: a scoping review beginning with the creation of the Brazilian Health Regulatory Agency.
Mota DM; Vigo Á; Kuchenbecker RS
Cad Saude Publica; 2018 Oct; 34(10):e00000218. PubMed ID: 30328994
[TBL] [Abstract][Full Text] [Related]
20. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
